TAVALISSE DIN 02508052
Status: Marketed
Holder: MEDISON PHARMA CANADA INC.
Molecule: FOSTAMATINIB (FOSTAMATINIB DISODIUM)
Available to quote
Health Canada record
| Active ingredient(s) | FOSTAMATINIB (FOSTAMATINIB DISODIUM) 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | B02BX09 FOSTAMATINIB |
| Original market date | 10-Dec-2020 |
| Current status date | 15-Aug-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Medison Pharma Canada Inc. — licence 3-002662, currently licensed, last inspection rating C (2026-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FOSTAMATINIB (FOSTAMATINIB DISODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02508060 | TAVALISSE | MEDISON PHARMA CANADA INC. | Tablet | FOSTAMATINIB (FOSTAMATINIB DISODIUM) 150 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26270 | 2021-07-15 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 24636 | 2020-11-19 | New Drug Submission (NDS) |